Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More
Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
Learn More
Webinar Wednesday: Overcome Biomarker Multiplexing Challenges in Drug Development
Paul Rhyne from BDS Shares Recommended Multiplexing Techniques
Paul Rhyne, PhD, Chief Scientific Officer at Biologic Development Services (BDS), shares insights from a review article co-authored with 11 colleagues from pharmaceutical companies, clinical research organizations (CRO), and government agencies over two years titled: Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
March 8
Luminex Corporation to Present at the Barclays Global Healthcare Conference
February 12
Luminex Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
February 6
Luminex Corporation To Present At LEERINK Partners 7th Annual Global Healthcare Conference
January 24
Luminex Corporation Declares First Quarter Cash Dividend
January 7
Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017
ECCMID
21-24 April
Madrid, Spain
ESPID
28 May – 2 June
Malmo, Sweden
PSI Annual Meeting
3-6 June
Beurs Van Berlage, Amsterdam
Drug Discovery Summit
7-8 June
Berlin, Germany
KIT
20-23 June
Cologne, Germany
